Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.66 |
| ▸ | PDE6C | P51160 | 2/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6200033 | 0.90 | PDE5A (0.66) | PDE5APDE6C | |
| Trifluoroacetic Acid SCHEMBL6198723 | 0.87 | PDE5A (0.59) | PDE5APDE6CHDAC1 | |
| SCHEMBL6810957 | 0.81 | PDE5A (0.50) | PDE5A | |
| SCHEMBL6773299 | 0.80 | PDE5A (1.00) | PDE5APDE6C | |
| SCHEMBL6204272 | 0.79 | PDE5A (0.65) | PDE5APDE6C | |
| SCHEMBL6358922 | 0.79 | PDE5A (0.85) | PDE5APDE6C | |
| Trifluoroacetic Acid SCHEMBL6199599 | 0.77 | PDE5A (0.70) | PDE5APDE6C | |
| SCHEMBL6783033 | 0.75 | PDE5A (0.85) | PDE5APDE6C | |
| SCHEMBL6805069 | 0.74 | PDE5A (0.52) | PDE5A | |
| SCHEMBL6776131 | 0.74 | PDE5A (0.86) | PDE5APDE6C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1372656-B1 | PYRAZOLO[4,3-D]PYRIMIDINONE COMPOUNDS AS CGMP PDE INHIBITORS | PFIZER LTD (GB) | 2005-06-22 | — | — | EP | disclosed |
| US-6784185-B2 | PYRAZOLO(4,3-D) PYRIMIDINONE COMPOUNDS USEFUL AS CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASES (CGMP PDES) INHIBITOR | PFIZER INC. | 2004-08-31 | — | — | US | disclosed |
| US-20020198223-A1 | Pharmaceutically active compounds | PFIZER INC. | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198223-A1 | Pharmaceutically active compounds | PDE5A, PDE3A, PDE2A | PDE5A 1/4885PDE6C 22/4885HDAC1 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.